IMNN - Gunggunge utang jangka dawa imunon.com

This chart of Imunon, Inc. (IMNN) asset value on the GURU.Markets platform reflects the dynamics of long-term liabilities, which currently stand at 0.01. The company is implementing IT systems for the digital design of genetic drugs, reducing manual labor for scientists. Robotic complexes allow for a manifold increase in the number of weekly tests. However, oncology research costs are creating a financial deficit and increasing the company's market vulnerability.

This indicator measures total liabilities with maturities exceeding one year, reflecting the dependence of cash flows on the cost of servicing borrowed capital. Analyzing the long-term debt of Imunon, Inc. (IMNN) allows for an assessment of the company's financial stability when funding costly developments in DNA cancer immunotherapy, determining the balance between credit leverage and investments in scientific innovation.